Timber Pharmaceuticals, Inc.
TMBRAMEXHealthcare
$0.34
+$0.00(+0.74%)
Market Cap$1176057
P/E Ratio—
52W High$3.39
52W Low$0.32
Timber Pharmaceuticals, Inc. (TMBR) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · TMBR · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2020-01 | 2019-01 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.08M | $0.30M | $0.45M | $0.32M | $0.06M |
| Cost of Revenue | $13.30M | $6.15M | $1.50M | $3.38M | $0.08M |
| Gross Profit | ($13.22M) | ($5.85M) | ($1.05M) | ($3.06M) | ($0.03M) |
| Gross Margin %(computed) | — | — | -230.78% | -941.95% | -45.61% |
| Operating Expenses | |||||
| R&D Expenses | $13.30M | $6.15M | $15.10M | $3.38M | $9.08M |
| G&A Expenses | $0.00M | $0.00M | $0.00M | $0.00M | $5.24M |
| Total Operating Expenses | $19.24M | $10.95M | $18.71M | $0.59M | $16.48M |
| Operating Income | ($19.24M) | ($10.65M) | ($20.21M) | ($3.64M) | ($17.23M) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00M | $0.02M | $0.82M | $0.00M | $0.00M |
| Interest Expense | $0.23M | $0.02M | $4.42M | $0.00M | $0.03M |
| Income Before Tax | ($19.37M) | ($10.67M) | ($15.08M) | ($3.69M) | ($17.26M) |
| Income Tax Expense | $0.01M | ($0.03M) | $0.04M | ($0.00M) | $0.00M |
| Net Income | ($19.38M) | ($10.64M) | ($15.12M) | ($3.69M) | ($17.26M) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-9.19 | $-13.15 | $-48.15 | $-29.31 | $-1340.11 |
| Wtd Avg Shares | 2.11M | 0.81M | 0.31M | 0.13M | 0.01M |
| EBITDA | ($19.16M) | ($10.38M) | ($17.78M) | ($0.05M) | ($17.17M) |
| EBITDA Margin %(computed) | — | — | — | -14.03% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · M
Explore more Timber Pharmaceuticals, Inc. data
About Timber Pharmaceuticals, Inc. (TMBR) Income Statement
Timber Pharmaceuticals, Inc. (TMBR) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2022, TMBR reported revenue of $0.00B, gross profit of ($0.01B) (gross margin -15892.35%), and net income of ($0.02B) — a net profit margin of -23299.05%.
Frequently asked questions
TMBR · 4 questionsTimber Pharmaceuticals, Inc. (TMBR) reported revenue of $0.00B for 2022, down 71.9% year-over-year.
TMBR revenueTMBR salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09